Premium
PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B ‐CELL LYMPHOMA ( RRPMBCL ): UPDATED RESULTS FROM THE KEYNOTE ‐013 TRIAL
Author(s) -
Zinzani P.,
Ribrag V.,
Moskowitz C.H.,
Michot J.,
Kuruvilla J.,
Bartlett N.,
Balakumaran A.,
Chatterjee A.,
Chlosta S.,
Shipp M.A.,
Armand P.
Publication year - 2017
Publication title -
hematological oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.918
H-Index - 44
eISSN - 1099-1069
pISSN - 0278-0232
DOI - 10.1002/hon.2438_50
Subject(s) - medicine , tolerability , neutropenia , pembrolizumab , regimen , adverse effect , population , cohort , refractory (planetary science) , surgery , oncology , gastroenterology , toxicity , cancer , immunotherapy , physics , environmental health , astrobiology
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom